MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by YAMAMURA, H.
Right arrow Articles by FAIN, J. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by YAMAMURA, H.
Right arrow Articles by FAIN, J. N.

Molecular Pharmacology, Vol 12, 693-700, Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics

Hydroxybenzylpindolol and Hydroxybenzylpropranolol: Partial Beta Adrenergic Agonists of Adenylate Cyclase in the Rat Adipocyte

HIROHEI YAMAMURA 1, MARTIN RODBELL 1, and JOHN N. FAIN 2

1 Membrane Regulation Section, Laboratory of Nutrition and Endocrinology, National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health, Bethesda, Maryland 20014
2 Division of Biological and Medical Sciences, Brown University, Providence, Rhode Island 02912

Hydroxybenzylpindolol stimulates adenylate cyclase activity in purified plasma membranes from the rat adipocyte. The intrinsic activity of hydroxybenzylpindolol is about 35% less than that of isoproterenol and is inhibited stereoselectively by (-)-propranolol. Thus hydroxybenzylpindolol is both a partial agonist and an antagonist of catecholamine activation of adenylate cyclase. Hydroxybenzylpropranolol, the corresponding derivative of the antagonist propranolol, is also a partial agonist, although considerably weaker than hydroxybenzylpindolol and about equivalent in intrinsic activity to pindolol. Based on the relative inhibitory effects of propranolol, the affinities of the beta receptor for hydroxybenzylpindolol and hydroxybenzylpropranolol are equivalent but are about 10 times that of pindolol or propranolol and 25-40 times that of isoproterenol. The stimulatory effects of the partial agonists are mediated by the same guanine nucleotide regulatory process observed with catecholamines. The potency and intrinsic activity exhibited by hydroxybenzylpindolol on adenylate cyclase in isolated membranes correlated with its stimulatory effect on cyclic 3',5'-AMP accumulation and lipolysis in intact fat cells. Hydroxybenzylpindolol increased lipolysis and cyclic AMP accumulation by intact fat cells at a concentration of 10 nM, while isoproterenol was without effect at this concentration. However, at higher concentrations hydroxybenzylpindolol gave a maximal activation of either parameter which was about one-third that due to isoproterenol.

Submitted on October 7, 1975
Accepted on April 2, 1976







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics